A detailed history of Qube Research & Technologies LTD transactions in Innoviva, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 11,326 shares of INVA stock, worth $201,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,326
Previous 17,901 36.73%
Holding current value
$201,489
Previous $293,000 25.6%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$16.33 - $20.04 $107,369 - $131,763
-6,575 Reduced 36.73%
11,326 $218,000
Q2 2024

Aug 14, 2024

SELL
$14.4 - $16.4 $391,464 - $445,833
-27,185 Reduced 60.3%
17,901 $293,000
Q1 2024

May 14, 2024

BUY
$14.56 - $16.78 $656,452 - $756,543
45,086 New
45,086 $687,000
Q3 2022

Nov 14, 2022

SELL
$11.61 - $15.22 $213,438 - $279,804
-18,384 Reduced 12.63%
127,203 $1.48 Million
Q2 2022

Aug 15, 2022

BUY
$14.32 - $19.88 $1.35 Million - $1.87 Million
94,155 Added 183.07%
145,587 $2.15 Million
Q1 2022

May 09, 2022

BUY
$15.39 - $20.25 $67,654 - $89,019
4,396 Added 9.35%
51,432 $995,000
Q4 2021

Feb 01, 2022

BUY
$15.91 - $18.72 $748,342 - $880,513
47,036 New
47,036 $811,000
Q2 2021

Aug 13, 2021

SELL
$11.45 - $13.96 $273,609 - $333,588
-23,896 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$11.06 - $12.87 $264,289 - $307,541
23,896 New
23,896 $286,000
Q4 2020

Feb 16, 2021

SELL
$9.33 - $12.48 $308,692 - $412,913
-33,086 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$10.33 - $14.49 $341,778 - $479,416
33,086 New
33,086 $346,000
Q2 2020

Aug 14, 2020

SELL
$11.49 - $15.26 $217,965 - $289,482
-18,970 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$8.11 - $15.23 $153,846 - $288,913
18,970 New
18,970 $223,000

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.24B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.